The role of E2F2 in cancer progression and its value as a therapeutic target

被引:3
|
作者
Gao, Yang [1 ,2 ]
Qiao, Xinjie [3 ]
Liu, Zhenhui [1 ,2 ]
Zhang, Wenzhou [1 ,2 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Dept Rhinol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
cancer progression; therapeutic target; function; strategy; CELL-PROLIFERATION; GASTRIC-CANCER; PROMOTES PROLIFERATION; REGULATING E2F2; DOWN-REGULATION; POOR-PROGNOSIS; DNA-BINDING; TRANSCRIPTION; DP; INHIBITION;
D O I
10.3389/fimmu.2024.1397303
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The E2F family of transcription factors plays a crucial role in the regulation of cell cycle progression and cell proliferation. Accumulative evidence indicates that aberrant expression or activation of E2F2 is a common phenomenon in malignances. E2F2 has emerged as a key player in the development and progression of various types of tumors. A wealth of research has substantiated that E2F2 could contribute to the enhancement of tumor cell proliferation, angiogenesis, and invasiveness. Moreover, E2F2 exerts its influence on a myriad of cellular processes by engaging with a spectrum of auxiliary factors and downstream targets, including apoptosis and DNA repair. The dysregulation of E2F2 in the context of carcinogenesis may be attributable to a multitude of mechanisms, which encompass modifications in upstream regulatory elements or epigenetic alterations. This review explores the function of E2F2 in cancer progression and both established and emerging therapeutic strategies aiming at targeting this oncogenic pathway, while also providing a strong basis for further research on the biological function and clinical applications of E2F2.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data
    Zeng, Zhili
    Cao, Zebiao
    Tang, Ying
    BMC CANCER, 2020, 20 (01)
  • [32] E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle
    Sun, Jing
    Shi, Run
    Zhao, Sha
    Li, Xiaona
    Lu, Shan
    Bu, Hemei
    Ma, Xianghua
    Su, Chuan
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
  • [33] miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2
    Wu, Ning
    Xiao, Lin
    Zhao, Xiangzhong
    Zhao, Jin
    Wang, Jianpeng
    Wang, Fengxia
    Cao, Shousong
    Lin, XiuKun
    FEBS LETTERS, 2012, 586 (21) : 3831 - 3839
  • [34] MAP kinases may mediate regulation of the cell cycle in rice by E2F2 phosphorylation
    Singh, Dhanraj
    Banerjee, Gopal
    Verma, Neetu
    Sinha, Alok Krishna
    FEBS LETTERS, 2023, 597 (23) : 2993 - 3009
  • [35] Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2
    Wang, Huaidong
    Zhang, Xiaotian
    Liu, Yuxin
    Ni, Zhaohui
    Lin, Yan
    Duan, Zipeng
    Shi, Yue
    Wang, Guoqing
    Li, Fan
    ONCOTARGET, 2016, 7 (24) : 36577 - 36589
  • [36] Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target
    Yu, Weina
    Yang, Li
    Li, Ting
    Zhang, Yi
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [37] Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis
    Opavsky, Rene
    Tsai, Shih-Yin
    Guimond, Martin
    Arora, Anjulie
    Opavska, Jana
    Becknell, Brian
    Kaufmann, Michael
    Walton, Nathaniel A.
    Stephens, Julie A.
    Fernandez, Soledad A.
    Muthusamy, Natarajan
    Felsher, Dean W.
    Porcu, Pierluigi
    Caligiuri, Michael A.
    Leone, Gustavo
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) : 15400 - 15405
  • [38] Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target
    Fang, Xian-long
    Cao, Xue-ping
    Xiao, Jun
    Hu, Yun
    Chen, Mian
    Raza, Hafiz Khuram
    Wang, Huai-yuan
    He, Xu
    Gu, Jin-fa
    Zhang, Kang-jian
    JOURNAL OF DRUG TARGETING, 2024, 32 (03) : 223 - 240
  • [39] The emerging roles of IDO2 in cancer and its potential as a therapeutic target
    Li, Pengcheng
    Xu, Weiqi
    Liu, Furong
    Zhu, He
    Zhang, Lu
    Ding, Zeyang
    Liang, Huifang
    Song, Jia
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [40] Protection of CpG islands against de novo DNA methylation during oogenesis is associated with the recognition site of E2f1 and E2f2
    Saadeh, Heba
    Schulz, Reiner
    EPIGENETICS & CHROMATIN, 2014, 7